Syndax Pharmaceuticals(SNDX)

Focus: Syndax is a publicly traded oncology-focused biopharmaceutical company specializing in tumor phenotype modification with a commercial product in leukemia and an extensive pipeline across multiple cancer types.

Oncology Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Syndax Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Syndax Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

FY2025

Key Products

REVUFORJ

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

Growth

Help build intelligence for Syndax Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Revumenib

Relapsed/Refractory Acute Leukemia

N/A

Clinical Trials (1)

NCT05918913Expanded Access Program for Revumenib

N/A

Revumenib

Relapsed/Refractory Leukemias

Phase 1

Clinical Trials (1)

NCT05326516A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Phase 1

entinostat

Breast Cancer

Phase 1

Clinical Trials (1)

NCT02820961Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

Phase 1

SNDX-275

Breast Cancer

Phase 1

Clinical Trials (1)

NCT00754312A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

Phase 1

entinostat

Lung Cancer

Phase 1

Clinical Trials (1)

NCT01594398Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Phase 1

Entinostat

Renal Impairment

Phase 1

Clinical Trials (1)

NCT03192111A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

Phase 1

Entinostat

Fallopian Tube Cancer

Phase 1

Entinostat

Metastatic Breast Cancer

Phase 1

Clinical Trials (1)

NCT03473639A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

Phase 1

Entinostat

Neoplasms

Phase 1

Clinical Trials (1)

NCT02897778Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Phase 1

Entinostat

Volunteers

Phase 1

Clinical Trials (1)

NCT02922946Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat

Phase 1

Entinostat

Pancreas Cancer

Phase 1

Clinical Trials (1)

NCT03760614A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

Phase 1

entinostat

Volunteers

Phase 1

Clinical Trials (1)

NCT02922933A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

Phase 1

Entinostat

Neoplasms

Phase 1

Revumenib

Refractory Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT06177067Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1

Revumenib

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AML

Phase 1

Entinostat

Drug Interaction

Phase 1

Clinical Trials (1)

NCT03187015A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

Phase 1

Revumenib

Blinatumomab

Phase 1

SNDX-5613

Acute Myeloid Leukemias

Phase 1

Clinical Trials (1)

NCT06226571A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Phase 1

Axatilimab

Solid Tumor

Phase 1

Clinical Trials (1)

NCT03238027A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Phase 1

Revumenib

Acute Leukemia

Phase 1

Clinical Trials (1)

NCT05406817Study of Radiolabeled Revumenib in Adults With Acute Leukemia

Phase 1

Entinostat

Breast Cancer

Phase 1

Clinical Trials (1)

NCT03361800Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Phase 1

revumenib

Acute Myeloid Leukemia

Phase 1/2

Clinical Trials (1)

NCT04065399A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1/2

Atezolizumab

Metastatic Cancer

Phase 1/2

Entinostat

Breast Cancer

Phase 1/2

entinostat

Non-Small Cell Lung Cancer

Phase 1/2

entinostat

Epithelial Ovarian Cancer

Phase 1/2

SNDX-5613

Acute Myeloid Leukemia

Phase 1/2

Venetoclax

Acute Myeloid Leukemia

Phase 1/2

Revumenib

Colorectal Cancer

Phase 1/2

Clinical Trials (1)

NCT05731947Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Phase 1/2

Entinostat

Non-Small-Cell Lung Carcinoma

Phase 1/2

Clinical Trials (1)

NCT00602030Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Phase 1/2

axatilimab

Chronic Graft-versus-host-disease

Phase 1/2

Clinical Trials (1)

NCT03604692A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD

Phase 1/2

Axatilimab

Idiopathic Pulmonary Fibrosis

Phase 2

Clinical Trials (1)

NCT06132256MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Entinostat

Renal Cell Carcinoma

Phase 2

Clinical Trials (1)

NCT03501381High Dose IL 2 and Entinostat in RCC

Phase 2

Pembrolizumab

Bladder Cancer

Phase 2

Entinostat

Non Small Cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT00750698A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Phase 2

entinostat

Estrogen Receptor-negative Breast Cancer

Phase 2

Clinical Trials (1)

NCT01234532Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

Phase 2

Entinostat

Hodgkin's Lymphoma

Phase 2

Clinical Trials (1)

NCT00866333A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Revumenib

Leukemia

Phase 2

Clinical Trials (1)

NCT06229912A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

Phase 2

Azacitidine

Non-Small Cell Lung Cancer

Phase 2

Pembrolizumab

Metastatic Uveal Melanoma

Phase 2

SNDX-6352

Coronavirus

Phase 2

Clinical Trials (1)

NCT04415073A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Phase 2

Entinostat

Lymphoma

Phase 2

Entinostat

Melanoma

Phase 2

Clinical Trials (1)

NCT03765229An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

Phase 2

Axatilimab

Chronic Graft-versus-host-disease

Phase 2

Clinical Trials (1)

NCT04710576A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

Phase 2

entinostat

Breast Cancer

Phase 2

Clinical Trials (1)

NCT00676663Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

Phase 2

Durvalumab

Unresectable Intrahepatic Cholangiocarcinoma

Phase 2

Entinostat

Metastatic Cholangiocarcinoma

Phase 2

Fulvestrant

Breast Cancer

Phase 2

Clinical Trials (1)

NCT02115594Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer

Phase 2

Entinostat

Renal Cell Carcinoma

Phase 2

Entinostat

ER+ Breast Cancer

Phase 2

Clinical Trials (1)

NCT00828854Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Phase 2

Syndax Pharmaceuticals(SNDX)

About Syndax Pharmaceuticals

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Pipeline & Clinical Trials

Open Jobs (0)

Financials (FY2025)